Sutro Biopharma (NASDAQ:STRO) Sets New 1-Year High - Still a Buy?

Key Points

• Hit a new 52‑week high: STRO traded as high as $39.74 intraday and has seen notable analyst support—Wall Street consensus is a "Moderate Buy" with an average target of $40.78 and several firms raising price targets (Deutsche Bank to $55).
• Still unprofitable for years: Lifesci and other forecasts show multi‑year losses (large negative EPS through FY2028–FY2030), creating near‑term dilution and execution risk despite bullish momentum.
• Heavy institutional positioning: Institutions own roughly 96.99% of the shares, with recent large moves such as AQR adding ~1.2 million shares, indicating concentrated hedge‑fund/institution interest.

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $39.74 and last traded at $37.1620, with a volume of 43157 shares changing hands. The stock had previously closed at $38.39.

Trending Headlines about Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Lifesci Capital issued a "Strong‑Buy" rating and detailed multi‑year forecasts that are materially less negative than the current consensus, signaling analyst conviction that losses will narrow over time (Lifesci FY2027 -$5.45 vs. consensus -$9.17). This can support buyer interest despite near‑term losses. MarketBeat: Lifesci Capital Estimates
• Neutral Sentiment: Lifesci provided detailed quarter‑by‑quarter EPS forecasts (example highlights: Q1 2026 -$2.78, Q2 2026 -$1.52, Q3/Q4 2026 -$1.34 each) and long‑range EPS for FY2026–FY2030. These numbers give a clearer roadmap for expected cash‑burn and recovery timing but are forecasts rather than confirmed results.
• Negative Sentiment: The firm remains projected to be deeply unprofitable for several years (FY2026 est. -$6.60; FY2028–FY2030 still showing multi‑dollar losses), which sustains downside risk and explains downward price pressure today as investors weigh near‑term dilution and execution risk.

Wall Street Analyst Weigh In

STRO has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Sutro Biopharma from $51.00 to $55.00 and gave the company a "buy" rating in a report on Wednesday, March 25th. Citizens Jmp raised their price target on shares of Sutro Biopharma from $35.00 to $41.00 and gave the stock a "market outperform" rating in a report on Thursday, April 23rd. HC Wainwright upgraded shares of Sutro Biopharma from a "neutral" rating to a "buy" rating and raised their price target for the stock from $10.00 to $28.00 in a report on Tuesday, March 24th. Lifesci Capital upgraded shares of Sutro Biopharma to a "strong-buy" rating in a report on Friday. Finally, Wall Street Zen upgraded shares of Sutro Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, March 28th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $40.78.

Sutro Biopharma Stock Performance

The stock has a market cap of $614.76 million, a P/E ratio of -1.42 and a beta of 1.63. The firm's fifty day simple moving average is $25.73 and its 200-day simple moving average is $16.52.

Institutional Trading of Sutro Biopharma

Several large investors have recently modified their holdings of STRO. AQR Capital Management LLC grew its position in shares of Sutro Biopharma by 1,052.8% during the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company's stock worth $859,000 after buying an additional 1,206,330 shares during the period. Jane Street Group LLC acquired a new stake in Sutro Biopharma in the 2nd quarter valued at $492,000. Jacobs Levy Equity Management Inc. acquired a new stake in Sutro Biopharma in the 3rd quarter valued at $387,000. Two Sigma Investments LP grew its position in Sutro Biopharma by 244.8% in the 3rd quarter. Two Sigma Investments LP now owns 396,785 shares of the company's stock valued at $345,000 after purchasing an additional 281,717 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Sutro Biopharma in the 2nd quarter valued at $166,000. Institutional investors and hedge funds own 96.99% of the company's stock.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.